Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (5K08NS102398-02)
Received: 30 August 2019
Accepted: 10 June 2020
First Online: 3 July 2020
Change Date: 20 August 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
: M.H.P. declares that he is a consultant and has equity interest in CRISPR Tx and Allogene Tx, and he states that neither company has had input or opinions on the subject matter described in this manuscript. The other authors declare no competing interests.